Thursday, March 15, 2012
Oncothyreon Inc., of Seattle, said it enrolled the first patient in a Phase I trial of ONT-10, a therapeutic vaccine directed at MUC1. The study is designed to evaluate the safety and immunogenicity of the vaccine in patients with cancers that commonly express MUC1, including breast, non-small-cell lung, ovarian, colorectal, prostate, pancreatic and gastric cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.